Sex-Differential Health Interventions In Low-Birth-Weight Infants

• ClinicalTrials.gov Identifier: NCT00625482
• Recruitment Status: Completed
• First Posted: February 28, 2008
• Last Update Posted: April 23, 2021
• Sponsor: Bandim Health Project
• Collaborators: March of Dimes; Danida
• Information provided by: Bandim Health Project

Study Description

Brief Summary:

Our group has consistently found that the major interventions to reduce morbidity and mortality in low-income countries have sex-differential effects. These interventions include BCG vaccine, oral polio vaccination (OPV), and vitamin A supplementation (VAS).

Low-birth-weight (LBW) children constitute the largest high-risk group in low-income countries. According to current policy, they receive OPV at birth. Current evidence suggests that a policy of providing BCG with OPV for girls and VAS instead of OPV for boys at birth may improve survival in LBW neonates. This will be tested in a large randomized trial.

We experienced an unexpected cluster of deaths among boys in the VAS arm, which could be due to chance, but we decided to stop randomizing boys to OPV or VAS. Very recent evidence has suggested that low-birth-weight boys may benefit from BCG at birth as well. Hence, we have obtained ethical permission to continue the trial with randomization of boys to OPV or OPV plus BCG.

Condition or disease	Intervention/treatment	Phase
Mortality; Morbidity; Growth; Neonatal Mortality	Biological: OPV; Biological: OPV plus BCG	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Primary Purpose: Prevention
• Official Title: Sex-Differential Health Interventions In Low-Birth-Weight Infants
• Study Start Date: February 2008

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Boys 1; OPV as usual	Biological: OPV
Experimental: Boys 2; OPV plus BCG	Biological: OPV plus BCG
Active Comparator: Girls 1; OPV as usual	Biological: OPV
Experimental: Girls 2; OPV plus BCG	Biological: OPV plus BCG

Outcome Measures

Primary Outcome Measures :

1. Mortality

Secondary Outcome Measures :

1. Overall severe morbidity as measured by number of hospitalizations
2. Morbidity due to rotavirus and malaria
3. Growth
4. BCG scar formation and PPD delayed type hypersensitivity (DTH) response
5. Changes in cytokine profile

Eligibility Criteria

• Ages Eligible for Study: up to 1 Month (Child)
• Sexes Eligible for Study: All

Criteria

Inclusion Criteria:

• Low-birth-weight infants (<2500 g)

Exclusion Criteria:

• Already received BCG/OPV
• Overtly sick or have malformations at the time of enrolment
• Clinical signs of vitamin A deficiency (very unlikely)

Contacts and Locations

Locations

Guinea-Bissau

Bandim Health Project

Bissau, Guinea-Bissau

Sponsors and Collaborators

Bandim Health Project

March of Dimes

Danida

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Schaltz-Buchholzer F, Berendsen M, Roth A, Jensen KJ, Bjerregaard-Andersen M, Kjaer Sorensen M, Monteiro I, Aaby P, Stabell Benn C. BCG skin reactions by 2 months of age are associated with better survival in infancy: a prospective observational study from Guinea-Bissau. BMJ Glob Health. 2020 Sep;5(9):e002993. doi: 10.1136/bmjgh-2020-002993.

Jensen KJ, Biering-Sorensen S, Ursing J, Kofoed PL, Aaby P, Benn CS. Seasonal variation in the non-specific effects of BCG vaccination on neonatal mortality: three randomised controlled trials in Guinea-Bissau. BMJ Glob Health. 2020 Mar 5;5(3):e001873. doi: 10.1136/bmjgh-2019-001873. eCollection 2020.

Schaltz-Buchholzer F, Biering-Sorensen S, Lund N, Monteiro I, Umbasse P, Fisker AB, Andersen A, Rodrigues A, Aaby P, Benn CS. Early BCG Vaccination, Hospitalizations, and Hospital Deaths: Analysis of a Secondary Outcome in 3 Randomized Trials from Guinea-Bissau. J Infect Dis. 2019 Jan 29;219(4):624-632. doi: 10.1093/infdis/jiy544.

Biering-Sorensen S, Aaby P, Lund N, Monteiro I, Jensen KJ, Eriksen HB, Schaltz-Buchholzer F, Jorgensen ASP, Rodrigues A, Fisker AB, Benn CS. Early BCG-Denmark and Neonatal Mortality Among Infants Weighing <2500 g: A Randomized Controlled Trial. Clin Infect Dis. 2017 Oct 1;65(7):1183-1190. doi: 10.1093/cid/cix525.

Biering-Sorensen S, Jensen KJ, Monterio I, Ravn H, Aaby P, Benn CS. Rapid Protective Effects of Early BCG on Neonatal Mortality Among Low Birth Weight Boys: Observations From Randomized Trials. J Infect Dis. 2018 Feb 14;217(5):759-766. doi: 10.1093/infdis/jix612.

Biering-Sorensen S, Jensen KJ, Aamand SH, Blok B, Andersen A, Monteiro I, Netea MG, Aaby P, Benn CS, Haslov KR. Variation of growth in the production of the BCG vaccine and the association with the immune response. An observational study within a randomised trial. Vaccine. 2015 Apr 21;33(17):2056-65. doi: 10.1016/j.vaccine.2015.02.056. Epub 2015 Mar 10.

Lund N, Biering-Sorensen S, Andersen A, Monteiro I, Camala L, Jorgensen MJ, Aaby P, Benn CS. Neonatal vitamin A supplementation associated with a cluster of deaths and poor early growth in a randomised trial among low-birth-weight boys of vitamin A versus oral polio vaccine at birth. BMC Pediatr. 2014 Aug 28;14:214. doi: 10.1186/1471-2431-14-214.

Eriksen HB, Biering-Sorensen S, Lund N, Correia C, Rodrigues A, Andersen A, Ravn H, Aaby P, Jeppesen DL, Benn CS. Factors associated with thymic size at birth among low and normal birth-weight infants. J Pediatr. 2014 Oct;165(4):713-21. doi: 10.1016/j.jpeds.2014.06.051. Epub 2014 Jul 30.

• ClinicalTrials.gov Identifier: NCT00625482
• Other Study ID Numbers: 2007-7041-121
• First Posted: February 28, 2008
• Last Update Posted: April 23, 2021
• Last Verified: April 2021

Keywords provided by Bandim Health Project:

BCG vaccine; Oral polio vaccine; Vitamin A supplementation; Low-birth-weigth; Sex-differential; Prevention; Immunological parameters

Additional relevant MeSH terms:

Birth Weight; Body Weight